122 related articles for article (PubMed ID: 30274827)
1. ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol.
Stamp LK; Wallace M; Roberts RL; Frampton C; Miner JN; Merriman TR; Dalbeth N
Drug Metab Pharmacokinet; 2018 Dec; 33(6):241-242. PubMed ID: 30274827
[No Abstract] [Full Text] [Related]
2. Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2.
Nakamura M; Fujita K; Toyoda Y; Takada T; Hasegawa H; Ichida K
Drug Metab Pharmacokinet; 2018 Feb; 33(1):77-81. PubMed ID: 29342419
[TBL] [Abstract][Full Text] [Related]
3. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population.
Zhang K; Li C
Hereditas; 2019; 156():26. PubMed ID: 31367212
[TBL] [Abstract][Full Text] [Related]
5. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
6. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.
Wallace MC; Roberts RL; Nanavati P; Miner JN; Dalbeth N; Topless R; Merriman TR; Stamp LK
Rheumatology (Oxford); 2018 Apr; 57(4):656-660. PubMed ID: 29342288
[TBL] [Abstract][Full Text] [Related]
7. [ROLE OF SLC2A9 AND ABCG2 GENE POLYMORPHISMS IN ORIGIN OF HYPERURICEMIA AND GOUT].
Fadieieva A; Prystupa L; Pogorelova O; Kirichenko N; Dudchenko I
Georgian Med News; 2016 Mar; (252):79-83. PubMed ID: 27119840
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.
Brackman DJ; Yee SW; Enogieru OJ; Shaffer C; Ranatunga D; Denny JC; Wei WQ; Kamatani Y; Kubo M; Roden DM; Jorgenson E; Giacomini KM
Clin Pharmacol Ther; 2019 Sep; 106(3):623-631. PubMed ID: 30924126
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout.
Roberts RL; Wallace MC; Phipps-Green AJ; Topless R; Drake JM; Tan P; Dalbeth N; Merriman TR; Stamp LK
Pharmacogenomics J; 2017 Mar; 17(2):201-203. PubMed ID: 26810134
[TBL] [Abstract][Full Text] [Related]
10. The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics.
Hishe HZ; Stocker SL; Stamp LK; Dalbeth N; Merriman TR; Phipps-Green A; Wright DFB
Clin Transl Sci; 2023 Mar; 16(3):422-428. PubMed ID: 36398357
[TBL] [Abstract][Full Text] [Related]
11. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Vora B; Brackman DJ; Zou L; Garcia-Cremades M; Sirota M; Savic RM; Giacomini KM
Clin Transl Sci; 2021 Jul; 14(4):1431-1443. PubMed ID: 33931953
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk.
Li R; Miao L; Qin L; Xiang Y; Zhang X; Peng H; Mailamuguli ; Sun Y; Yao H
Int J Clin Exp Pathol; 2015; 8(9):9812-23. PubMed ID: 26617691
[TBL] [Abstract][Full Text] [Related]
13. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
14. The association between the polymorphism rs2231142 in the ABCG2 gene and gout risk: a meta-analysis.
Lv X; Zhang Y; Zeng F; Yin A; Ye N; Ouyang H; Feng D; Li D; Ling W; Zhang X
Clin Rheumatol; 2014 Dec; 33(12):1801-5. PubMed ID: 24777469
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
[TBL] [Abstract][Full Text] [Related]
16. Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis.
Dong Z; Guo S; Yang Y; Wu J; Guan M; Zou H; Jin L; Wang J
Int J Rheum Dis; 2015 May; 18(4):382-91. PubMed ID: 25639607
[TBL] [Abstract][Full Text] [Related]
17. Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk.
Tu HP; Ko AM; Chiang SL; Lee SS; Lai HM; Chung CM; Huang CM; Lee CH; Kuo TM; Hsieh MJ; Ko YC
J Rheumatol; 2014 Apr; 41(4):749-58. PubMed ID: 24532835
[TBL] [Abstract][Full Text] [Related]
18. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout.
Tu HP; Min-Shan Ko A; Lee SS; Lee CP; Kuo TM; Huang CM; Ko YC
J Hum Genet; 2018 Jan; 63(1):63-70. PubMed ID: 29215084
[TBL] [Abstract][Full Text] [Related]
19. No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat.
Stamp LK; Topless R; Miner JN; Dalbeth N; Merriman T
Rheumatology (Oxford); 2019 Mar; 58(3):547-548. PubMed ID: 30597115
[No Abstract] [Full Text] [Related]
20. [Recent progress and prospects for research on urate efflux transporter ABCG2].
Ichida K
Nihon Rinsho; 2014 Apr; 72(4):757-65. PubMed ID: 24796111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
